Compare · DRMA vs LLY
DRMA vs LLY
Side-by-side comparison of Dermata Therapeutics Inc. (DRMA) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRMA and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.18T, about 261288.5x DRMA ($4.5M).
- Over the past year, DRMA is down 80.5% and LLY is up 55.4% - LLY leads by 135.9 points.
- LLY has been more active in the news (19 items in the past 4 weeks vs 2 for DRMA).
- LLY has more recent analyst coverage (25 ratings vs 2 for DRMA).
- Company
- Dermata Therapeutics Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $4.5M
- $1.18T
- 1M return
- -27.79%
- +9.10%
- 1Y return
- -80.53%
- +55.40%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 19
- Recent ratings
- 2
- 25
Dermata Therapeutics Inc.
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest DRMA
- Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
- SEC Form S-3 filed by Dermata Therapeutics Inc.
- Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
- Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
- PRESIDENT, CHAIRMAN, CEO Proehl Gerald T was granted 170,068 shares (SEC Form 4)
- SVP, CFO Van Hoose Kyri K. was granted 102,040 shares, increasing direct ownership by 78% to 232,463 units (SEC Form 4)
- SEC Form 25-NSE filed by Dermata Therapeutics Inc.
- Dermata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease